Oric Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $8.41
- Today's High:
- $9.01
- Open Price:
- $8.8
- 52W Low:
- $2.36
- 52W High:
- $9.788
- Prev. Close:
- $8.86
- Volume:
- 202207
Company Statistics
- Market Cap.:
- $506.06 million
- Book Value:
- 4.929
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.19%
- Return on Equity TTM:
- -36.61%
Company Profile
Oric Pharmaceuticals Inc had its IPO on 2020-04-24 under the ticker symbol ORIC.
The company operates in the Healthcare sector and Biotechnology industry. Oric Pharmaceuticals Inc has a staff strength of 89 employees.
Stock update
Shares of Oric Pharmaceuticals Inc opened at $8.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $8.41 - $9.01, and closed at $8.45.
This is a -4.63% slip from the previous day's closing price.
A total volume of 202,207 shares were traded at the close of the day’s session.
In the last one week, shares of Oric Pharmaceuticals Inc have slipped by -8.94%.
Oric Pharmaceuticals Inc's Key Ratios
Oric Pharmaceuticals Inc has a market cap of $506.06 million, indicating a price to book ratio of 0.6485 and a price to sales ratio of 0.
In the last 12-months Oric Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-92503000. The EBITDA ratio measures Oric Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Oric Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -21.19% with a return of equity of -36.61%.
In Q2, Oric Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Oric Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oric Pharmaceuticals Inc’s profitability.
Oric Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5978. Its price to sales ratio in the trailing 12-months stood at 0.
Oric Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $291.82 million
- Total Liabilities
- $14.53 million
- Operating Cash Flow
- $-19313000.00
- Capital Expenditure
- $405000
- Dividend Payout Ratio
- 0%
Oric Pharmaceuticals Inc ended 2024 with $291.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $291.82 million while shareholder equity stood at $268.80 million.
Oric Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $14.53 million in other current liabilities, 6000.00 in common stock, $-381119000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $103.68 million and cash and short-term investments were $264.16 million. The company’s total short-term debt was $2,704,000 while long-term debt stood at $0.
Oric Pharmaceuticals Inc’s total current assets stands at $268.36 million while long-term investments were $9.58 million and short-term investments were $160.48 million. Its net receivables were $0 compared to accounts payable of $3.19 million and inventory worth $0.
In 2024, Oric Pharmaceuticals Inc's operating cash flow was $-19313000.00 while its capital expenditure stood at $405000.
Comparatively, Oric Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.45
- 52-Week High
- $9.788
- 52-Week Low
- $2.36
- Analyst Target Price
- $13.5
Oric Pharmaceuticals Inc stock is currently trading at $8.45 per share. It touched a 52-week high of $9.788 and a 52-week low of $9.788. Analysts tracking the stock have a 12-month average target price of $13.5.
Its 50-day moving average was $8.36 and 200-day moving average was $5.98 The short ratio stood at 20.36 indicating a short percent outstanding of 0%.
Around 2424.3% of the company’s stock are held by insiders while 7539.3% are held by institutions.
Frequently Asked Questions About Oric Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.